GlassScriptPhysician profile
Howard G Wold
NPI 1467455501
$7,632.61
in general payments reported to CMS, 2019-2025
60 companies · $251 in 2025
The $251 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,493 · 2020: $953 · 2021: $2,180 · 2022: $525 · 2023: $1,132 · 2024: $97.95 · 2025: $251.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,409 · Education: $72.73.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,408.78 |
| Education | $72.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $851.35 | 2019-2025 | Darzalex, Tecvayli, Carvykti |
| E.R. Squibb & Sons, L.L.C. | $669.53 | 2019-2023 | Pomalyst, Reblozyl, Opdivo |
| Astrazeneca Pharmaceuticals LP | $620.03 | 2019-2024 | Lynparza |
| Merck Sharp & Dohme LLC | $518.02 | 2019-2025 | Keytruda |
| Novartis Pharmaceuticals Corporation | $461.74 | 2019-2022 | |
| Amgen INC. | $424.96 | 2019-2023 | Nplate, Xgeva, Vectibix |
| Incyte Corporation | $347.72 | 2019-2023 | Jakafi |
| Bayer Healthcare Pharmaceuticals INC. | $258.71 | 2019-2025 | |
| Gilead Sciences, INC. | $252.95 | 2021-2024 | Trodelvy |
| Celgene Corporation | $230.40 | 2019-2021 | |
| Pfizer INC. | $207.29 | 2019-2021 | |
| Beigene USA, INC. | $167.83 | 2020-2023 | Brukinsa |
| Takeda Pharmaceuticals U.S.A., INC. | $167.07 | 2019-2021 | |
| Kyowa Kirin, INC. | $147.38 | 2019-2020 | |
| Genzyme Corporation | $140.54 | 2019-2021 |
Show all 60 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Howard Wold listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.